Bisphosphonates may reduce risk of certain breast, colon, and lung cancers
the ONA take:
According to two new studies published in the journal Proceedings of the National Academy of Sciences (PNAS), researchers at the Icahn School of Medicine at Mount Sinai in New York, New York, have found that bisposphonates, a commonly used class of drug to treat osteoporosis, may also prevent certain types of breast, colon, and lung cancers.
The first study analyzes how bisphosphonates block abnormal tumor growth through the human epidermal growth factor (HER) receptors, and the second study describes how bisphosphonates could be used in cancer prevention, in combination with existing treatments, and against treatment-resistant cancers. Certain types of breast, colon, and non-small cell lung cancers are driven by genetic mutations that cause the overexpression of HER family receptors.
The study found that bisphosphonates bind to kinase domains for HER proteins, thereby preventing pathway signaling that would ultimately cause cancer growth. This mechanism is similar to that of drugs that inhibit tyrosine kinases like trastuzumab and erlotinib; however, cancers often become resistant to these treatments after the tumor develops a second genetic mutation.
The findings suggest that bisphosphonates may continue to inhibit HER family receptors even after a second mutation is present, making these drugs a potential treatment for those cancers that become resistant to primary therapy.
Bisposphonates may also prevent certain types of breast, colon, and lung cancers.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Aligning Patient Goals With End of Life Treatment Decisions
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|